公开(公告)号：US20240335470A1

公开(公告)日：2024-10-10

申请号：US18266493

申请日：2021-12-10

申请人： OSPEDALE PEDIATRICO BAMBINO GESU'

发明人： Concetta QUINTARELLI ,  Biagio DE ANGELIS ,  Franco LOCATELLI

IPC分类号： A61K35/17 ,  A61K39/00 ,  A61P35/02 ,  C07K16/28 ,  C12N5/0783 ,  C12N15/85

CPC分类号： A61K35/17 ,  A61K39/4611 ,  A61K39/4613 ,  A61K39/4631 ,  A61K39/464412 ,  A61K39/464413 ,  A61K39/464424 ,  A61P35/02 ,  C07K16/2803 ,  C07K16/2887 ,  C12N5/0636 ,  C12N5/0646 ,  C12N15/85 ,  A61K2239/13 ,  A61K2239/17 ,  A61K2239/21 ,  A61K2239/25 ,  A61K2239/48

摘要： CAR T cells for treating CD19+, CD20+ OR CD22+ tumors, including leukemia and lymphoid malignances, provide increased safety in the therapy of the tumors and prevent epitope masking in CAR+ B-cell leukemia blasts. The CAR T cells decrease the potential risk of CD19−/CAR+, CD20−/CAR+ or CD22−/CAR+ leukemic relapse. In addition, the CAR T cells provide increased safety in the treatment of autoimmune diseases caused by B cells producing auto-antibodies.

公开(公告)号：US20240050566A1

公开(公告)日：2024-02-15

申请号：US18361787

申请日：2023-07-28

申请人： TAKEDA PHARMACEUTICAL COMPANY LIMITED

发明人： Shuxia ZHOU ,  Lan Cao ,  Dayong Gao ,  Qiong Xue ,  Jiusong Sun ,  Huang Zhu

IPC分类号： A61K39/00 ,  A01N1/02 ,  C12N5/0783 ,  A61P35/00

CPC分类号： A61K39/4613 ,  A01N1/0284 ,  C12N5/0646 ,  A61K39/4631 ,  A61P35/00 ,  C12N2510/00 ,  A61K2239/13 ,  A61K2239/21 ,  A61K2239/25

摘要： The present disclosure provides, among other things, a method of cryopreserving and thawing cells that results in the thawed cells having high cellular viability and functionality post-thawing. In some embodiments, a large-scale method of cryopreserving cells is provided, the method comprising: (a) contacting the cells with a cryopreservation medium; (b) cooling the cells to −80° C. at a controlled rate to minimize latent heat of fusion; and (c) storing the cells in liquid nitrogen vapor phase, thereby cryopreserving the immune cells.

公开(公告)号：US20240000838A1

公开(公告)日：2024-01-04

申请号：US18255095

申请日：2021-11-24

申请人： SIMCERE INNOVATION, INC.

发明人： Daofeng LIU ,  Pei-Yun TSAI ,  Zhongdong SHI ,  Xiangbin XU

IPC分类号： A61K35/17 ,  C12N5/0783 ,  A61K39/00 ,  C12N15/86 ,  A61P35/02

CPC分类号： A61K35/17 ,  C12N5/0646 ,  A61K39/4613 ,  A61K39/4631 ,  C12N15/86 ,  A61P35/02 ,  A61K2239/21 ,  A61K2239/17 ,  A61K2239/48 ,  A61K2239/25

摘要： Compositions and methods for treating diseases associated with expression of cluster differentiation 33 (CD33) and/or cluster differentiation 5 (CD5) involve two chimeric antigen receptors (CARs) specific to CD33 and CD5 and T cells with CD33 and CD5 dual-CAR. Methods of administering a genetically modified T cell expressing the dual-CAR can be used for autologous and allogeneic treatment of T cell malignancies.

公开(公告)号：US20230242611A1

公开(公告)日：2023-08-03

申请号：US18107573

申请日：2023-02-09

申请人： Yeda Research and Development Co. Ltd.

发明人： Rachel Lea EISENBACH ,  David BASSAN ,  Yosi GOZLAN ,  Esther TZEHOVAL ,  Nir FRIEDMAN ,  Erez GREENSTEIN

IPC分类号： C07K14/725 ,  C12N9/78 ,  A61K39/00 ,  A61P35/00

CPC分类号： C07K14/7051 ,  C12Y305/04005 ,  C12N9/78 ,  A61K39/4632 ,  A61K39/4611 ,  A61K39/464486 ,  A61P35/00 ,  A61K39/4637 ,  A61K2239/25

摘要： MAGE-A1 specific T cell receptors (TCRs) are provided. Accordingly, there is provided a TCR comprising a TCR α chain as set forth in SEQ ID NO: 1 having at least one mutation at an amino acid position selected from the group consisting of S189, G125, W55 and Y56; and/or a TCR β chain as set forth in SEQ ID NO: 2 having at least one mutation at an amino acid position selected from the group consisting of S32, S109 and T63, the TCR binds a MAGE-A1 peptide as set forth in SEQ ID NO: 25. Also provided are polynucleotides encoding the TCR and T cells expressing same and methods of use thereof.

公开(公告)号：US20240358761A1

公开(公告)日：2024-10-31

申请号：US18682798

申请日：2022-08-11

申请人： Sana Biotechnology, Inc.

发明人： Sonja SCHREPFER

IPC分类号： A61K35/17 ,  A61K31/365 ,  A61K31/436 ,  A61K31/5377 ,  A61K31/573 ,  A61K31/675 ,  A61K35/30 ,  A61K35/36 ,  A61K35/39 ,  A61K35/44 ,  A61K35/55 ,  A61K38/13 ,  A61K39/00 ,  A61K45/06 ,  C07K14/705 ,  C12N9/22 ,  C12N15/11 ,  C12N15/86 ,  C12N15/90 ,  G01N33/68

CPC分类号： A61K35/17 ,  A61K31/365 ,  A61K31/436 ,  A61K31/5377 ,  A61K31/573 ,  A61K31/675 ,  A61K35/30 ,  A61K35/36 ,  A61K35/39 ,  A61K35/44 ,  A61K35/55 ,  A61K38/13 ,  A61K39/4611 ,  A61K39/4631 ,  A61K39/464429 ,  A61K45/06 ,  C07K14/70596 ,  C12N9/22 ,  C12N15/111 ,  C12N15/86 ,  C12N15/907 ,  G01N33/6854 ,  A61K2239/25 ,  A61K2239/38 ,  C12N2310/20 ,  C12N2740/15043 ,  G01N2333/70539 ,  G01N2800/24 ,  G01N2800/52

摘要： Provided are engineered cells containing one or more modifications, such as genetic modifications, for use in allogeneic cell therapy. In some embodiments, the engineered cells are hypoimmunogenic cells.

公开(公告)号：US20240350544A1

公开(公告)日：2024-10-24

申请号：US18640982

申请日：2024-04-19

申请人： Takeda Pharmaceutical Company Limited

发明人： Michael Curley ,  Ertan Eryilmaz ,  Shawn Jennings ,  LeeAnn Talarico ,  Taylor Hickman ,  Christina Sheau Fen Wong ,  Kathryn Fraser ,  Haiqing Wang ,  Alessandra Piersigilli

IPC分类号： A61K35/17 ,  A61K39/00 ,  A61K47/20 ,  A61K47/26 ,  A61K47/42 ,  A61P35/02 ,  C07K16/28

CPC分类号： A61K35/17 ,  A61K39/4613 ,  A61K39/4631 ,  A61K39/464416 ,  A61K47/20 ,  A61K47/26 ,  A61K47/42 ,  A61P35/02 ,  C07K16/2878 ,  A61K2239/13 ,  A61K2239/21 ,  A61K2239/25 ,  A61K2239/48 ,  C07K2317/565

摘要： This present invention relates to BCMA binders (e.g. antibodies) and chimeric antigen receptor (CAR) constructs comprising a BCMA antigen binding molecule. The BCMA binders specifically bind to BCMA. The present BCMA CARs further comprise a hinge region (e.g., CD28 hinge), a transmembrane domain, and one or more intracellular NK cell signalling domains. NK cells expressing a BCMA CAR has increased efficacy in killing cancer cells. Provided herein also include therapeutic uses of the BCMA binders and BCMA CARs.

公开(公告)号：US20240091260A1

公开(公告)日：2024-03-21

申请号：US18454684

申请日：2023-08-23

申请人： Fred Hutchinson Cancer Center

发明人： Soheil Meshinchi ,  Danielle Kirkey ,  Anisha Loeb ,  Quy H. Le

IPC分类号： A61K35/17 ,  A61K38/21 ,  A61K39/00 ,  A61P35/02 ,  C07K14/74

CPC分类号： A61K35/17 ,  A61K38/217 ,  A61K39/4611 ,  A61K39/4631 ,  A61K39/464411 ,  A61P35/02 ,  C07K14/70539 ,  A61K2239/15 ,  A61K2239/21 ,  A61K2239/22 ,  A61K2239/25 ,  A61K2239/48

摘要： Chimeric antigen receptors (CAR) that bind Preferentially Expressed Antigen in Melanoma (PRAME) ALY(SEQ ID NO: 94)/HLA-A2 are disclosed. The CAR can be used to treat PRAME/HLA-A2 expressing cancers such as the t(8;21), Inv(16), and KMT2A-r forms of acute myeloid leukemia (AML).

公开(公告)号：US20230330227A1

公开(公告)日：2023-10-19

申请号：US18020728

申请日：2021-08-12

申请人： A2 Biotherapeutics, Inc.

发明人： Jee Young Mock ,  Carl Alexander Kamb ,  Agnes Hamburger

IPC分类号： A61K39/00 ,  C12N5/0783 ,  C12N15/86 ,  C07K14/47 ,  C07K14/72 ,  A61K31/138 ,  C07K14/725

CPC分类号： A61K39/4611 ,  C12N5/0636 ,  C12N15/86 ,  C07K14/4747 ,  C07K14/721 ,  A61K31/138 ,  A61K39/4621 ,  A61K39/4637 ,  A61K39/46431 ,  A61K39/4631 ,  C07K14/7051 ,  C12N2740/15043 ,  C07K2319/00 ,  A61K2239/25

摘要： The disclosure relates to fusion proteins comprising a tBID polypeptide and a steroid hormone receptor domain, and methods of using same to induce apoptosis in cells.